{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a
to a specific field?
Status:
Investigational
Source:
NCT01329913: Phase 1 Interventional Completed Hepatitis C
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MK-6325 is a potent HCV NS3/4A protease inhibitor patented by Merck Sharp & Dohme Corp for treating or preventing HCV infections. In 2011 MK-6325 was studied in phase I clinical trials but no further development reports were published.
Status:
Investigational
Source:
NCT02288481: Phase 1 Interventional Completed Tuberculosis
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
TBA-354, also known as SN31354, is a potent anti-tuberculosis drug candidate. TBA-354 is narrow spectrum and bactericidal in vitro against replicating and nonreplicating Mycobacterium tuberculosis, with potency similar to that of delamanid and greater than that of PA-824. TBA-354 maintains activity against Mycobacterium tuberculosis H37Rv isogenic monoresistant strains and clinical drug-sensitive and drug-resistant isolates. TBA-354 is a promising next-generation nitroimidazole antitubercular agent. TBA-354 emerged from studies designed to identify a next generation nitroimidazole for TB. TB Alliance conducted the studies in collaboration with the University of Auckland and University of Illinois-Chicago. Once identified, TB Alliance further advanced TBA-354 through pre-clinical development and is now the sponsor of the Phase 1 study.
Status:
Investigational
Source:
NCT04260256: Phase 2 Interventional Recruiting Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit
(2022)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02181491: Not Applicable Interventional Completed Cocaine Dependence
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02003092: Phase 1/Phase 2 Interventional Terminated Solid Tumor
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03110549: Phase 1 Interventional Terminated Human Immunodeficiency Virus
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MX-100 (also known as PL-100) is a benzenesulfonamide derivative patented by Pharmacor Inc as HIV aspartyl protease inhibitor. MX-100 retained excellent antiviral activity against almost all of these protease inhibitor-resistant viruses and that its performance in this regard was superior to those of atazanavir, amprenavir, indinavir, lopinavir, nelfinavir, and saquinavir. In almost every case, the increase in the EC50 for MX-100 observed with viruses containing multiple mutations in protease was far less than that obtained with the other drugs. Preclinical studies showed that MX-100 possessed suboptimal solubility and pharmacokinetic, (PK) properties, possibly hindering further development. MX-100 successfully completed preclinical and clinical development (phase I in healthy volunteers) and have been licensed to Merck in 2006
Status:
Investigational
Source:
Muscle Nerve. Jan 2021;63(1):31-39.: Phase 2 Human clinical trial Completed Amyotrophic Lateral Sclerosis/mortality
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Mivazerol is a new and selective alpha 2-adrenoceptor agonist, devoid of hypotensive effects, which has been designed to prevent adverse cardiac outcome in perioperative patients with, or at risk coronary artery disease. This compound, which lacks hypotensive effects, has been demonstrated to prevent hyperadrenergic activity and myocardial ischemia in perioperative patients and tachycardia in rats at emergence from halothane anesthesia. This type of ischemia, frequently encountered in postoperative patients, is considered to be a consequence of stress-induced hyperactivation of the sympathetic system. Anti-ischemic effects of this compound have been demonstrated in different animal models of myocardial ischemia, and Mivazerol has also been shown to improve exercise-induced ischemia in patients with angina pectoris.
Status:
Investigational
Source:
NCT03886662: Phase 1/Phase 2 Interventional Recruiting Myelodysplastic Syndromes
(2019)
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Investigational
Source:
NCT03539575: Not Applicable Interventional Active, not recruiting Drug Dependence
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
11C-JHU75528 (also known as 11C-OMAR) is a radiotracer with suitable imaging properties for quantification of cannabinoid receptor, CB1R in the human brain. 11C-JHU75528 is participating in an ongoing phase I clinical trial to examine whether the use of cannabis alters CB1R availability in females and if the severity of cannabis withdrawal is correlated with CB1 receptor availability.
